Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Intercell Announces Pediatric Approval of IXIARO® in the U.S.

Published: Thursday, May 23, 2013
Last Updated: Thursday, May 23, 2013
Bookmark and Share
FDA now approved IXIARO® for use in children from the age of 2 months.

Intercell AG has announced that the pediatric indication for IXIARO®, a vaccine to protect against Japanese Encephalitis (JE), was approved by the U.S. Food and Drug Administration (FDA). In Europe, the pediatric label extension was granted in February 2013.

“We are very pleased that the FDA has now approved IXIARO® for use in children from the age of 2 months. For the first time in nearly 2 years, a licensed vaccine will now be available to vaccinate also traveling children and those children of forward deployed military personal in Asia, against JE. This important step is a key element of the further growth for Intercell’s first commercial product and another milestone in the fight against this potentially deadly disease with a licensed vaccine", says Thomas Lingelbach, Chief Executive Officer of Intercell AG.

Intercell submitted applications for pediatric licensure of the JE vaccine to major regulatory agencies in late Q2 2012 based on data from a Phase III clinical study conducted in the Philippines and favorable interim data from a second Phase III trial in EU, U.S. and Australia.

In both studies, the JE vaccine was shown to be highly immunogenic in children/adolescents aged 2 months to less than 18 years with a safety profile comparable to pediatric vaccines licensed for other diseases.

Following the approval and launch of Intercell's vaccine against Japanese Encephalitis for adult civilian travelers and military personnel in Europe, Switzerland, United States, Canada, Hong Kong, Singapore, Israel (IXIARO®) and Australia and New Zealand (JESPECT®), the development of a vaccine to protect children traveling to endemic areas from Japanese Encephalitis has been a major goal of the Company.

Intercell’s next-generation vaccine to protect travelers against Japanese Encephalitis (JE) is currently licensed in more than 35 countries worldwide, and is the Company’s first product on the market.

Extension of the approved indication to include the pediatric age segment in the U.S. allows IXIARO® to be administered to both adults and children aged 2 months and above who travel to, or live in, JEV endemic areas of Asia.

Intercell and its marketing and distribution partners are committed to introducing a new product presentation for IXIARO®, suitable for administration in all approved age groups, as soon as possible.

Product which is currently available on the market in the U.S. can be used in accordance with the approved dosage and administration in individuals aged 3 years and above.

The vaccine is manufactured by Intercell AG’s wholly-owned subsidiary Intercell Biomedical Ltd. at its cGMP facility in Livingston, Scotland.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Intercell Completes Equity Private Placement of EUR 15.2 Million at a Price of EUR 2.30 Per New Share
Bringing total volume of combined debt and equity financing to EUR 35.2 million.
Tuesday, May 15, 2012
Intercell Starts a Pivotal Phase II/III Efficacy Study with its Pseudomonas Aeruginosa Vaccine Candidate
First interim data are expected mid-2013.
Tuesday, March 20, 2012
Intercell Announces New Management Structure
Company’s Supervisory Board has appointed Thomas Lingelbach as new Chief Executive Officer for Intercell.
Friday, May 06, 2011
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!